Experience of using different dosages of the drug kalimate in order to correct hyperkalemia in chronic kidney disease
https://doi.org/10.36485/1561-6274-2022-26-1-50-56
Abstract
THE AIM: to evaluate the efficacy, safety, and tolerability of the preparation of calcium polystyrene sulfonate (Kalimate ® ), clinical observation was conducted in patients with chronic kidney disease who do not need dialysis, using different dosages of the drug with incomplete effectiveness of the hypokalemic diet as monotherapy for hyperkalemia.
PATIENTS AND METHODS: the study included 70 patients suffering from chronic kidney disease who do not need renal replacement therapy, and with a plasma potassium level of 5.5 mmol/l or higher, after the use of hypokalemic diet therapy was ineffective. The patients were divided into 4 groups depending on the dose of calcium polystyrene sulfate. The 3 groups differed in the dose of the drug taken, the 4th group consisted of patients with reduced nutrition. Patients in all groups underwent control studies of serum potassium concentration before the start of the study, after 1 week, after 2 weeks, after 1 month, after 3, and after 6 months of treatment.
RESULTS: The decrease in the level of potassium in the blood serum of group 1 patients for 6 months was 24.15 % (95 % CI 16.32-31.4 %), which in absolute value was 1.485± 0.513 mmol/l. Similar parameters for groups 2, 3 and 4 were, respectively: 22.59 % (95 %CI 15.57–31.12 %) and 1.38±0.487 mmol/L, 19.72 % (95 %CI 12.08–25.32 %) and 1.215±0.45 mmol/L, 25.24 % (95 % CI 17.86–30.24 %) and 1.58±0.502 mmol/l.
CONCLUSION: the effectiveness of reducing serum potassium levels in patients with hyperkalemia on the background of chronic kidney disease who do not receive dialysis and follow only a hypokalemic diet, when using the drug polystyrene sulfate according to the instructions for 15-30 grams per day for at least 1 week with subsequent dose adjustment is an effective way of treating and correcting hyperkalemia.
About the Author
D. V. Artemov
Moscow Regional Research and Clinical Institute ("MONIKI") named after M.F. Vladimirsky
Russian Federation
Russian Federation
Artemov Dmitry Vladimirovich, Ph.D., Associate Professor of the Department
Department of Transplantology, Nephrology and Artificial Organs
129110, Moscow, Shchepkina str., 61/2, bldg. 6
Phone: +7(926)-528-96-52
References
1. Смирнов АВ, Шилов ЕМ, Добронравов ВА и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. СПб., Левша. Санкт-Петербург, 2012. 51с Smirnov AB, Shilov EM, Dobronravov VA et al. National recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Lefsha. St. Petersburg, 2012: 51
2. Hsieh MF, Wu IW, Lee CC et al. Higher serum potassium level associated with late stage chronic kidney disease. Chang Gung Med J 2011; 34: 418–425
3. Elliott MJ, Ronksley PE, Clase CM et al. Management of patients with acute hyperkalemia. CMAJ 2010; 182: 1631–1635
4. Evans BM, Jones NC, Milne MD et al. Ion-exchange resins in the treatment of anuria. Lancet 1953; 265: 791–795
5. Sterns RH, Rojas M, Bernstein P et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010; 21: 733–735
6. Nepal M, Bucaloiu ID, Norfolk ER. Hypernatremia in a patient treated with sodium polystyrene sulfonate. Int J Nephrol Renovasc Dis 2010; 3: 141–143
7. Chernin G, Gal-Oz A, Ben-Assa E et al. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy. Clin Cardiol 2012; 35: 32–36
8. Смирнов АВ, Кучер АГ, Каюков ИГ, Есаян АМ. Руководство по лечебному питанию для больных с хронической болезнью почек. Триада, СПб.-Тверь, 2009 Smirnov AV, Kucher AG, Kayukov IG, Yesayan AM. Guidelines for therapeutic nutrition for patients with chronic kidney disease. Triada, St. Petersburg-Tver, 2009
9. Sarafidis PA, Blacklock R, Wood E et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012; 7: 1234–1241
10. Pepin J, Shields C. Advances in diagnosis and management of hypokalemic and hyperkalemic emergencies. Emerg Med Pract 2012; 14: 1–17
11. Wakabayashi M, Shou I. Study on the dose response of a jelly preparation of polystyrene sulfonate calcium in hyperkalemia. Ther Res 2005; 1727–1733
12. Ватазин АВ, Шилов ЕМ, Хозяинова НЮ, Ермоленко ВМ, Земченков АЮ, Есаян АМ, Моргунов ЛЮ, Михайлова НА, Смоляков АА, Самсонов МЮ. Новые возможности коррекции гиперкалимии у пациентов с хронической болезнью почек. Нефрология 2016;20(4):47–53 Vatazin AV, Shilov EM, Khozyainova NY, Ermolenko VM, Zemchenkov AY, Essaian AM, Morgunov LY, Mikhailova NA, Smolyakov AA, Samsonov MY. New possibilities of correction of hyperkalemia in patients with chronic kidney disease. Nephrology (Saint-Petersburg) 2016;20(4):47–53 (In Russ.)
Review
For citations:
Artemov D.V. Experience of using different dosages of the drug kalimate in order to correct hyperkalemia in chronic kidney disease. Nephrology (Saint-Petersburg). 2022;26(1):50-56. (In Russ.) https://doi.org/10.36485/1561-6274-2022-26-1-50-56
Views:
1927
Email this article 